160 related articles for article (PubMed ID: 22967087)
1. Loss-of-heterozygosity on chromosome 19q in early-stage serous ovarian cancer is associated with recurrent disease.
Skirnisdottir I; Mayrhofer M; Rydåker M; Akerud H; Isaksson A
BMC Cancer; 2012 Sep; 12():407. PubMed ID: 22967087
[TBL] [Abstract][Full Text] [Related]
2. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
[TBL] [Abstract][Full Text] [Related]
3. Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study.
Høgdall EV; Ryan A; Kjaer SK; Blaakaer J; Christensen L; Bock JE; Glud E; Jacobs IJ; Høgdall CK
Cancer; 2004 Jun; 100(11):2387-95. PubMed ID: 15160342
[TBL] [Abstract][Full Text] [Related]
4. Allelotype of papillary serous peritoneal carcinomas.
Cass I; Baldwin RL; Fasylova E; Fields AL; Klinger HP; Runowicz CD; Karlan BY
Gynecol Oncol; 2001 Jul; 82(1):69-76. PubMed ID: 11426964
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of primary and recurrent ovarian serous carcinomas: comparative genomic hybridization analysis with a potential application for prognosis.
Hu J; Khanna V; Jones MW; Surti U
Gynecol Oncol; 2003 Jun; 89(3):369-75. PubMed ID: 12798697
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival.
Pieretti M; Hopenhayn-Rich C; Khattar NH; Cao Y; Huang B; Tucker TC
Cancer Invest; 2002; 20(1):11-23. PubMed ID: 11852993
[TBL] [Abstract][Full Text] [Related]
7. Loss of heterozygosity at chromosome 9q22-31 is a frequent and early event in ovarian tumors.
Byrom J; Mudaliar V; Redman CW; Jones P; Strange RC; Hoban PR
Int J Oncol; 2004 May; 24(5):1271-7. PubMed ID: 15067351
[TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of acquired uniparental disomy in serous ovarian cancer.
Tuna M; Ju Z; Smid M; Amos CI; Mills GB
Mol Cancer; 2015 Feb; 14(1):29. PubMed ID: 25644622
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer.
Manderson EN; Presneau N; Provencher D; Mes-Masson AM; Tonin PN
Mol Carcinog; 2002 Jun; 34(2):78-90. PubMed ID: 12112314
[TBL] [Abstract][Full Text] [Related]
10. The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome.
Wojnarowicz PM; Oros KK; Quinn MC; Arcand SL; Gambaro K; Madore J; Birch AH; de Ladurantaye M; Rahimi K; Provencher DM; Mes-Masson AM; Greenwood CM; Tonin PN
PLoS One; 2012; 7(9):e45484. PubMed ID: 23029043
[TBL] [Abstract][Full Text] [Related]
11. Early loss of heterozygosity on 17q in ovarian cancer. The Abe Ovarian Cancer Genetics Group.
Eccles DM; Russell SE; Haites NE; Atkinson R; Bell DW; Gruber L; Hickey I; Kelly K; Kitchener H; Leonard R
Oncogene; 1992 Oct; 7(10):2069-72. PubMed ID: 1408149
[TBL] [Abstract][Full Text] [Related]
12. Incidence of loss of heterozygosity at p53 and BRCA1 loci in serous surface carcinoma.
Quezado MM; Moskaluk CA; Bryant B; Mills SE; Merino MJ
Hum Pathol; 1999 Feb; 30(2):203-7. PubMed ID: 10029450
[TBL] [Abstract][Full Text] [Related]
13. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
[TBL] [Abstract][Full Text] [Related]
14. TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer.
Zhang M; Zhuang G; Sun X; Shen Y; Wang W; Li Q; Di W
Diagn Pathol; 2017 Feb; 12(1):16. PubMed ID: 28148293
[TBL] [Abstract][Full Text] [Related]
15. Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer.
Van Nieuwenhuysen E; Busschaert P; Laenen A; Moerman P; Han SN; Neven P; Lambrechts D; Vergote I
Neoplasia; 2019 Jun; 21(6):582-590. PubMed ID: 31054497
[TBL] [Abstract][Full Text] [Related]
16. Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas.
Choi C; Cho S; Horikawa I; Berchuck A; Wang N; Cedrone E; Jhung SW; Lee JB; Kerr J; Chenevix-Trench G; Kim S; Barrett JC; Koi M
Genes Chromosomes Cancer; 1997 Nov; 20(3):234-42. PubMed ID: 9365830
[TBL] [Abstract][Full Text] [Related]
17. Prediction of early-stage hepatocellular carcinoma using OncoScan chromosomal copy number aberration data.
Yu MC; Lee CW; Lee YS; Lian JH; Tsai CL; Liu YP; Wu CH; Tsai CN
World J Gastroenterol; 2017 Nov; 23(44):7818-7829. PubMed ID: 29209123
[TBL] [Abstract][Full Text] [Related]
18. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
Lee JM; Nair J; Zimmer A; Lipkowitz S; Annunziata CM; Merino MJ; Swisher EM; Harrell MI; Trepel JB; Lee MJ; Bagheri MH; Botesteanu DA; Steinberg SM; Minasian L; Ekwede I; Kohn EC
Lancet Oncol; 2018 Feb; 19(2):207-215. PubMed ID: 29361470
[TBL] [Abstract][Full Text] [Related]
19. Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis.
Gorringe KL; Ramakrishna M; Williams LH; Sridhar A; Boyle SE; Bearfoot JL; Li J; Anglesio MS; Campbell IG
Genes Chromosomes Cancer; 2009 Oct; 48(10):931-42. PubMed ID: 19603523
[TBL] [Abstract][Full Text] [Related]
20. Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization.
Hauptmann S; Denkert C; Koch I; Petersen S; Schlüns K; Reles A; Dietel M; Petersen I
Hum Pathol; 2002 Jun; 33(6):632-41. PubMed ID: 12152163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
